Skip to main content

Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.

Publication ,  Journal Article
Bordeaux, J; Blitzblau, R; Aasi, SZ; Alam, M; Amini, A; Bibee, K; Bolotin, D; Chen, P-L; Contreras, CM; DiMaio, D; Donigan, JM; Farma, JM ...
Published in: J Natl Compr Canc Netw
January 2025

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.

Duke Scholars

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 2025

Volume

23

Issue

1

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Medical Oncology
  • Humans
  • Dermatofibrosarcoma
  • Combined Modality Therapy
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bordeaux, J., Blitzblau, R., Aasi, S. Z., Alam, M., Amini, A., Bibee, K., … Espinosa, S. (2025). Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw, 23(1). https://doi.org/10.6004/jnccn.2025.0001
Bordeaux, Jeremy, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Diana Bolotin, et al. “Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.J Natl Compr Canc Netw 23, no. 1 (January 2025). https://doi.org/10.6004/jnccn.2025.0001.
Bordeaux J, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, et al. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Jan;23(1).
Bordeaux, Jeremy, et al. “Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.J Natl Compr Canc Netw, vol. 23, no. 1, Jan. 2025. Pubmed, doi:10.6004/jnccn.2025.0001.
Bordeaux J, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bolotin D, Chen P-L, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, LeBoeuf N, Lukens JN, Manber S, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha AR, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Jan;23(1).

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 2025

Volume

23

Issue

1

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Medical Oncology
  • Humans
  • Dermatofibrosarcoma
  • Combined Modality Therapy
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis